DNA Script Raises $165M in Oversubscribed Series C Financing to Accelerate Commercialization of Enzymatic DNA Printing Platform
Summary
New investors Fidelity Management and Research, Columbia Threadneedle Investments, Arrowmark Partners, Farallon Capital and Moore Strategic Ventures joined the round. DNA Script announced last June the targeted release of the SYNTAX System, a benchtop instrument along with software, and reagent kits. The fully automated instrument sets up in 15 minutes and within a few hours produces up to 96 oligos immediately ready for use in genomics and molecular biology research. The tremendous support we’ve received from the investment community validates our vision and will fuel our portfolio of continued innovation,” said Thomas Ybert, co-founder and CEO of DNA Script. This expansion of talent and resources will enable us to execute on EDS technology’s promise and our ambitious goals to drive DNA-on-demand further on the path to revolutionize life science research as well as personalized medicine.” Founded in 2014, DNA Script is a pioneering life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids.